TrialCancer science2017

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.

Naoya Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.